- $56.97m
- -$41.05m
- 27
- 99
- 46
- 58
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.6 | ||
| Price to Tang. Book | 0.6 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | -3.49 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 11.75% | ||
| Return on Equity | 14.29% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
AVROBIO, Inc. is a gene therapy company. The Company is focused on developing potentially curative hematopoietic stem cells (HSC) gene therapies to treat patients with rare diseases following a single dose treatment regimen. The gene therapies that the Company is engaged in developing employ HSCs that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The Company's development focus has been on a group of rare genetic diseases referred to as lysosomal disorders, primarily managed with enzyme replacement therapies (ERTs). Its pipeline is comprised of three HSC gene therapy programs, which include AVR-RD-02 for the treatment of Gaucher disease type 1 and type 3; AVR-RD-03 for the treatment of Pompe disease, and AVR-RD-01 for the treatment of Fabry disease.
Directors
- Bruce Booth NEC (46)
- Geoff Mackay PRE (54)
- Erik Ostrowski CFO (48)
- Christopher Mason CSO (63)
- Sean O'Bryan OTH
- Deanna Petersen OTH (59)
- Essra Ridha OTH
- Steven Avruch SEC (60)
- Ian Clark IND (60)
- Phillip Donenberg IND (60)
- Gail Farfel IND (57)
- Annalisa Jenkins IND (55)
- Christopher Paige IND (68)
- Philip Vickers IND (61)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- November 17th, 2015
- Public Since
- June 21st, 2018
- No. of Shareholders
- 5
- No. of Employees
- 13
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 44,860,515
- Address
- 100 TECHNOLOGY SQUARE, 6TH FLOOR, CAMBRIDGE, 02139
- Web
- https://www.avrobio.com/
- Phone
- +1 6179148420
- Contact
- Chris Brinzey
- Auditors
- Ernst & Young LLP
Upcoming Events for AVRO
AVROBIO Inc Annual Shareholders Meeting
Q2 2024 AVROBIO Inc Earnings Release
Similar to AVRO
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Avrobio share price?
As of Today at 19:03 UTC, shares in Avrobio are trading at $1.27. This share price information is delayed by 15 minutes.
How has the Avrobio share price performed this year?
Shares in Avrobio last closed at $1.27 and the price had moved by +32.98% over the past 365 days. In terms of relative price strength the Avrobio share price has outperformed the S&P500 Index by +7.4% over the past year.
What are the analyst and broker recommendations for Avrobio?
The overall consensus recommendation for Avrobio is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Avrobio dividend yield?
Avrobio does not currently pay a dividend.
Does Avrobio pay a dividend?
Avrobio does not currently pay a dividend.
When does Avrobio next pay dividends?
Avrobio does not currently pay a dividend.
How do I buy Avrobio shares?
To buy shares in Avrobio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Avrobio?
As of the previous close price of $1.27, shares in Avrobio had a market capitalisation of $56.97m.
Where are Avrobio shares listed?
Here are the trading details for Avrobio:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: AVRO
What kind of share is Avrobio?
Based on an overall assessment of its quality, value and momentum Avrobio is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Avrobio share price forecast for 2024?
The analyst consensus target price for shares in Avrobio is $2.00. That is 57.48% above the last closing price of $1.27.
Analysts covering Avrobio currently have a consensus Earnings Per Share (EPS) forecast of -$0.48 for the next financial year.
What is the trend in the Avrobio share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Avrobio. Over the past six months, its share price has underperformed the S&P500 Index by -30.5%.
As of the last closing price of $1.27, shares in Avrobio were trading -8.94% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Avrobio PE Ratio?
The Avrobio PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.27.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Avrobio?
Avrobio's management team is headed by:
- Bruce Booth - NEC
- Geoff Mackay - PRE
- Erik Ostrowski - CFO
- Christopher Mason - CSO
- Sean O'Bryan - OTH
- Deanna Petersen - OTH
- Essra Ridha - OTH
- Steven Avruch - SEC
- Ian Clark - IND
- Phillip Donenberg - IND
- Gail Farfel - IND
- Annalisa Jenkins - IND
- Christopher Paige - IND
- Philip Vickers - IND